A detailed history of Blue Path Capital Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Blue Path Capital Management, LLC holds 8,555 shares of GILD stock, worth $767,896. This represents 0.44% of its overall portfolio holdings.

Number of Shares
8,555
Previous 10,300 16.94%
Holding current value
$767,896
Previous $707 Million 1.5%
% of portfolio
0.44%
Previous 0.5%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$66.59 - $83.99 $116,199 - $146,562
-1,745 Reduced 16.94%
8,555 $717 Million
Q2 2024

Aug 05, 2024

BUY
$63.15 - $72.88 $186,924 - $215,724
2,960 Added 40.33%
10,300 $707 Million
Q1 2024

Apr 19, 2024

BUY
$71.58 - $87.29 $15,747 - $19,203
220 Added 3.09%
7,340 $538 Million
Q4 2023

Jan 11, 2024

BUY
$73.27 - $83.09 $67,994 - $77,107
928 Added 14.99%
7,120 $602 Million
Q3 2023

Oct 25, 2023

BUY
$73.94 - $80.67 $457,836 - $499,508
6,192 New
6,192 $464 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Blue Path Capital Management, LLC Portfolio

Follow Blue Path Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Path Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blue Path Capital Management, LLC with notifications on news.